Nutriband Inc Warrants (30/09/2026) NTRBW 深 沪
等待开盘 11-06 09:30:00 美东时间
2.15
-0.460
-17.62%
华盛通- 最 高2.15
- 今 开2.0501
- 成交量 721股
- 最 低 2.0501
- 昨 收 2.61
- 总市值 0
- 52周最高 5.25
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 1.00
- 委 比 -20.00%
- 总股本 --
- 历史最高 9.07
- 量 比 0
- 振 幅 3.83%
- 历史最低 0.1885
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nutriband Founder Gareth Sheridan Returns as CEO to Lead Company Toward 2026 NDA Filing, Serguei Melnik Steps Down
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei
10-27 19:09
Nutriband Co-Founder Gareth Sheridan Returns as CEO
Nutriband Inc. announced that founder Gareth Sheridan has returned as CEO, succeeding Co-Founder Serguei Melnik who led the company from August 10 to October 27. Sheridan will guide Nutriband toward the 2026 NDA filing for AVERSA Fentanyl, an innovative abuse-deterrent opioid patch designed to reduce misuse and accidental exposure. Targeting annual U.S. sales of $80–200 million, AVERSA Fentanyl addresses a global need for safer pain management. T...
10-27 11:00
Nutriband Signs Agreement Brand Institute For AVERSA Fentanyl, Plans To Commercialize Abuse-Deterrent Opioid Patch
Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system.Nutriband has partnered with Brand Institute, Inc, the global leader in pharmaceutical and
10-10 19:05
Nutriband Reports 50.87% Revenue Growth, $6.9M Cash; Advances AVERSA Fentanyl Toward NDA With No Phase 2/3 Trials Required
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the
09-10 21:20
Nutriband CEO Gareth Sheridan Steps Aside To Run For Irish Presidency, Chairman Serguei Melnik Takes Helm Ahead Of FDA Milestone
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company CEO, Gareth Sheridan will be stepping aside from his role for three months to enter the Irish Presidential election. The Nomination Hearings followed
08-11 17:07
Nutriband To Issue 25% Preferred Stock Dividend To Shareholders Of Record On July 25, Convertible Upon FDA Approval Of AVERSA Fentanyl
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend.Shareholders of record on July
07-18 21:37
Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
Nutriband Inc. is informing shareholders about upcoming key dates for its 25% Preferred stock dividend. Shareholders of record on July 25, 2025, will receive one preferred share for every four common shares held, with the payout on August 5. Each preferred share is convertible to one common share upon FDA approval of the company's AVERSA Fentanyl product, which uses abuse-deterrent transdermal technology. If unconverted, preferred shares will ear...
07-18 13:15
Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
Nutriband Inc. announced a 25% preferred stock dividend, with eligible shareholders receiving one preferred share for every four common shares held, based on July 25, 2025 records, payable on August 5. Each preferred share is convertible into one common share upon FDA approval of their AVERSA fentanyl product. If unconverted, preferred shares will receive annual cash dividends. The company focuses on developing abuse-deterrent fentanyl patches us...
07-02 12:05
Nutriband Completes Commercial Manufacturing Process Scale-Up For Aversa Fentanyl, With Kindeva
Nutriband and Kindeva have completed commercial manufacturing process scale-up for its lead product Aversa™ Fentanyl, an abuse-deterrent fentanyl patchNutriband is partnering with Kindeva to develop Aversa™
06-18 19:01
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
Nutriband Inc. announces the issuance of U.S. Patent No. 12,318,492 for its AVERSA™ abuse-deterrent transdermal technology, expanding its intellectual property protection in the U.S. This technology, which prevents drug abuse, misuse, and diversion, is already patented in 46 countries, including the U.S., Europe, Japan, China, and Australia. Nutriband's lead product, Aversa™ Fentanyl, an abuse-deterrent pain patch, has the potential to generate $...
06-09 11:30
